Emergent BioSolutions Inc

Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson’s COVID-19 Vaccine

04 Apr 2021 22:09:06 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19

02 Apr 2021 08:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

01 Mar 2021 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020

18 Feb 2021 16:05:01 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021

04 Feb 2021 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

10 Jan 2021 14:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

04 Jan 2021 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis

29 Dec 2020 16:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance

05 Nov 2020 16:05:03 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020

15 Oct 2020 06:30:10 By Nasdaq GlobeNewswire

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19

08 Oct 2020 16:05:10 By Nasdaq GlobeNewswire

Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day

31 Aug 2020 06:30:10 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of Directors

26 Aug 2020 06:30:10 By Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Virtual Investor Conferences

18 Aug 2020 06:31:56 By Nasdaq GlobeNewswire

UPDATE -- Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months

17 Aug 2020 11:54:37 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months

17 Aug 2020 06:30:10 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028

07 Aug 2020 16:05:10 By Nasdaq GlobeNewswire

NetDania - New 12 months High: Emergent BioSolutions Inc

06 Aug 2020 09:52:18 By NetDania Notify

NetDania - New 12 months High: Emergent BioSolutions Inc

05 Aug 2020 09:45:04 By NetDania Notify

Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028

04 Aug 2020 18:32:02 By Nasdaq GlobeNewswire